Ageing is associated with the decline in the capacity of the autophagy pathway to degrade dysfunctional and damaging cellular components, such as protein aggregates and mitochondria. Dysfunctional autophagy, in turn, undermines other cellular functions including DNA repair, metabolism and survival. Therefore, activation of autophagy is considered a promising therapeutic approach to combat ageing and age-related diseases. A large number of screens has been performed and published to date, these have identified a wide range of small molecules that stimulate initiation of autophagy. Prof. Korolchuck lab proposes to initiate a drug discovery program with the aim of identifying novel bioactive autophagy inducers.
Viktor Korolchuk
Research Lead
Time | Type | $VITA-FAST | USD | ETH | From |
|---|---|---|---|---|---|
Therapeutic Relevance
Two novel autophagy targets identified; 10-100x potency gains across three NCE rounds strongly…
Therapeutic Optionality
NPC, Alzheimer's, Parkinson's, broader LSDs, and longevity indications identified; dual…
Intellectual Property
First patent filed Dec 2025; novel compound IP planned; VitaFast LLC formed; favorable FTO vs mTOR…
Utility Of Candidates
Three lead NCEs and two repurposed molecules identified but computational optimization and formal…
Prospects For Safety
No cytotoxicity at therapeutic concentrations in cell assays; mechanism-specific rescue shown; but…